The Financial Channel of China Industrial Economic Information Network has learned that recently, China Le Kai Group Co., Ltd. (hereinafter referred to as Le Kai) listed and transferred 27 intangible assets (including 2 patents and 25 proprietary technologies, hereinafter referred to as the underlying assets). According to the appraisal report issued by the appraisal agency, the benchmark date of appraisal is May 365,438+0, 2020, which is based on the opening of the market. Combined with the actual situation of the underlying assets, considering various influencing factors, the market value of the underlying assets is evaluated by cost method and income method respectively, and the evaluation conclusion is the evaluation result of income method. As of the appraisal benchmark date, the market value of the underlying assets was 654.38+0.34579 million yuan, an increase of 654.38+0.34579 million yuan. The deadline for listing is September 9, 2020.
In order to accelerate the development of its subsidiary Le Kai Medical Technology Co., Ltd. (hereinafter referred to as Le Kai Medical) and better complete the serialization of medical dry film products, Le Kai Film decided to participate in the bidding for the patent technology transfer of medical film in Le Kai, China. On August 26th, 2020, the 5th meeting of the 8th Board of Directors held by Le Kai Film reviewed and unanimously passed the Proposal on Bidding for Patent Technology of Direct Thermal Imaging Silver Salt Digital Medical Film of China Le Kai Group Co., Ltd..
The main direction of Le Kai film is image information materials and new energy materials. The main products are solar cell backboard, colored paper, medical dry film, ink-jet printing paper, liquid medicine for processing information and image materials, lithium ion battery separator and other products. Le Kai Medical is mainly engaged in research and development, production and sales of information chemicals, fine chemical products and medical devices, with a registered capital of 654.38+30 million yuan, total assets of 4/kloc-0.80 million yuan and net assets of 359 million yuan. In the first half of 2020, the medical operating income of Le Kai was 2190,000 yuan, the total profit was 29.49 million yuan, and the net profit was 26.7922 million yuan.
It is reported that in the first half of 2020, the epidemic situation profoundly affected the image output market. In 2020 1 quarter, the registered population of marriage in China was 2.79 million couples, down 46% from 20 19. From June 5438 to May, the national passenger traffic was 310.5 billion, down 56.9% year-on-year. Professional enlargement and the civil photo market were hit at the same time, and the market demand dropped by more than 50% in the first half of the year. In the first half of the year, the sales revenue of Le Kai Film Company's products, especially video products, dropped sharply, and the company's profitability declined. In the first half of 2020, Le Kai Film realized an operating income of 869 million yuan, a year-on-year decrease of 65,438+09.58%; The net profit attributable to shareholders of listed companies was 27.8977 million yuan, a year-on-year decrease of 38.83%.
Therefore, finding new profit growth points has become the focus of Le Kai films at this stage. Facing the unfavorable situation of domestic image market, Le Kai film image sales promote sales by reducing customer cost and increasing product value, plan new products to go on the market, vigorously promote cost reduction measures, create "traceability code" quality certification photo album, and provide technical guidance and services for many environmental protection printing workshops remotely. Le Kai Film refines the promotion scheme of cloud movies and cloud images, realizes the embedding of all cloud movie software in the new self-service system, optimizes the software and hardware of the self-service system, and promotes the rapid development of cloud services. In the medical and industrial film market, sales measures were actively adjusted according to the impact of the epidemic, and product sales increased steadily.
After the successful introduction and industrialization of the patented technology, it will be used as a technical benchmark product for Le Kai Medical to enter the middle and high-end market, which can enrich the product categories, help to open up the market and enhance the market share, thus bringing income and profit growth to Le Kai Film. If Le Kai Medical successfully brings the direct thermal imaging silver salt digital medical film to the market, it can promote the serial development of medical film products, provide customers with mid-to high-end commodity choices and enhance the quality experience of users. At the same time, it can also greatly improve the market share of Le Kai Medical in the field of image consumables output. In the current increasingly fierce competition, product serialization is conducive to improving the profitability of Le Kai films, thus promoting the realization of the overall planning goals in the future.
After this transaction, Le Kai Medical will acquire all the property rights of the underlying intangible assets, and Le Kai, China will no longer use the intangible assets. The above bid assets are amortized to the future product cost of Le Kai Film for 7 years. However, the related technologies are all industrialized, and there is no mass production, so there is a risk of unsuccessful technology transformation.
Transfer from: China Industrial Economic Information Network